In This Section

Agenda

The SNMMI Therapeutics Conference has been developed to educate nuclear medicine physicians, technologists, hospital administrators, nurses, oncologists, and patients about the “how-to's” of establishing a nuclear medicine therapy program in their institution. This meeting will reach an audience that does not normally attend SNMMI meetings and who may not have the knowledge or resources of setting up or providing theranostic agents for their patients. 

Friday, October 25, 2019


Agenda will include:
  Exhibit Hours, Networking, Registration
      WelcomePhillip Koo, MD, Banner MD Anderson Cancer Center
      Introduction to TheranosticsDaniel Pryma, MD, University of Pennsylvania
     
  • NM physician as a clinician 
  • Setting up the care team 
      Establishing Your Practice in Systemic Radiation Therapy and the Role of Technologists in Theranostics Practice, Sandy McEwan, MD, Ipsen Pharmaceuticals
     
  • Operationalizing a 177Lu-Dotatate clinic, Jennifer Kwak, MD, University of Colorado
  • Operationalizing your practice for 223Ra-Dichloride, Phillip Koo, MD, Banner MD Anderson Cancer Center
  • Operationalizing your practice for 177Lu-PMSA based therapiesPhillip Kuo, MD, PhD, University of Arizona
      Radiation Safety and Medical Physics, Michael Sheetz, MS, CHP, DABMP, University of Pittsburgh
     
  • Primer for the Radiation Safety Officer
  • What the patient needs to know
  • Waste management
     

Discussion

      Exhibit Hall Welcome Reception

Saturday, October 26, 2019


Agenda will include: Incorporating new therapies into existing clinical practice 
      Breakfast
      Endocrine, Douglas Van Nostrand, MD, FACP, FACNM; Daniel Pryma, MD
     
  • Updates and Controversies of Radioiodine Theranostic in Differentiated Thyroid Cancer, Douglas Van Nostrand, MD, FACP, FACNM, MedStar Washington Hospital Center
  • The Role of I-131 MIBG in the treatment of neuroendocrine cancers, Daniel Pryma, MD, University of Pennsylvania
      GI TherapyChristopher Lieu, MD; Jennifer Kwak, MD, University of Colorado
     
  • Overview of the treatment landscape in neuroendocrine malignanciesChristopher Lieu, MD, University of Colorado; Jennifer Kwak, MD, University of Colorado
  • Optimizing the use of 177Lu-Dotatate in clinical practice and cases, Jennifer Kwak, MD, University of Colorado
      Morning Coffee Break
      GI Therapy Continued
     
  • Co-managing the patient with metastatic neuroendocrine diseaseChristopher Lieu, MD, University of Colorado
  • Discussion
      Lunch and Exhibits
      Prostate Therapy, Tanya Dorff, MD; Phillip Koo, MD; Phillip Kuo, MD, PhD
     
  • Overview of the treatment landscape in castration-resistant prostate cancer, Tanya Dorff, MD, City of Hope Comprehensive Cancer Center
  • The role of 223Ra-DichloridePhillip Koo, MD, Banner MD Anderson Cancer Center
  • Current status of 177Lu-PMSA based therapies and where will we be in the near futurePhillip Kuo, MD, PhD, University of Arizona 
  • Co-managing the patient with metastatic castration-resistant prostate cancer, Tanya Dorff, MD, City of Hope Comprehensive Cancer Center; Phillip Koo, MD, Banner MD Anderson Cancer Center; Phillip Kuo, MD, PhD, University of Arizona
  • Discussion

    "Meet the Sponsors" Happy Hour

Sunday, October 27, 2019


Agenda will include:

      Breakfast
      Billing and Regulatory Issues, Denise Merlino, CNMT, CPC, MBA, FSNMMI-TS, Merlino Health Care Consulting Corp; Shaemus Gleason, MD, Bayer
     
  • Coding and reimbursementDenise Merlino, CNMT, CPC, MBA, FSNMMIT, Merlino Health Care Consulting Corp
  • LicensingShaemus Gleason, MD, Bayer
      Roadmap/Overview/Wrap upPhillip Koo, MD, Banner MD Anderson Cancer Center; Daniel Pryma, MD, University of Pennsylvania 
     

Discussion/FAQs

     

Closing remarksPhillip Koo, MD, Banner MD Anderson Cancer Center; Daniel Pryma, MD, University of Pennsylvania